MedTrace Logo

Progesterone Primed Protocol Versus GnRH Antagonist in With PCO Undergoing ICSI

NCT05951400 · Status: COMPLETED · Phase: PHASE2/PHASE3 · Type: INTERVENTIONAL · Enrollment: 200

Last updated 2026-04-15

No results posted yet for this study

Summary

To compare the effectiveness and safety of Progesterone Primed Ovarian Stimulation protocol (PPOS) using Dydrogestrone vs GnRH Antagonist Protocol in patients with expected high ovarian response undergoing ICSI cycle

Conditions

  • IVF
  • PCO

Interventions

DRUG

Dydrogesterone Tablets

used for pituitary suppression in ICSI cycle

DRUG

Cetrorelix

GnRH antagonist for pituitary suppression

Sponsors & Collaborators

  • Beni-Suef University

    lead OTHER

Principal Investigators

  • Beni-Suef University · Faculty of Medicine Beni-Suef University

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
20 Years
Max Age
40 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2024-01-01
Primary Completion
2026-03-30
Completion
2026-04-05

Countries

  • Egypt

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05951400 on ClinicalTrials.gov